You are here: Home: Audio Program Guide: RCCU 1 | 2006 Audio Files

Go to interview with Nicholas J Vogelzang, MD
Go to Case Discussions
Go to interview with Ronald M Bukowski, MD
Go to interview with Janice P Dutcher, MD

To listen to individual tracks, click the on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.

Nicholas J Vogelzang, MD Director, Nevada Cancer Institute Professor of Medicine University of Nevada School of Medicine Las Vegas, Nevada     Click here to download the entire interview
Track 1	Introduction
Track 2	Biology and histology of clear cell cancer
Track 3	Pathogenesis of von Hippel-Lindau-mutated renal cell cancer
Track 4	Pathologic grade and outcome of renal cell carcinoma
Track 5	Mechanisms of action of novel biologic agents in renal cell cancer
Track 6	Biologic rationale for lack of responsiveness to chemotherapy for renal cell cancer
Track 7	Evolution of therapeutics in renal cell cancer
Track 8	Management of patients with renal cell cancer
Track 9	Role of the mTOR inhibitor temsirolimus in patients with poor-risk disease
Track 10	First- and second-line therapy for patients with good- to intermediate-risk disease
Track 11	Sorafenib-associated toxicity and side effects
Track 12	Sunitinib-associated side effects and tolerability
Track 13	Mechanisms of action of oral multikinase inhibitors (MKIs)
Track 14	Selection of patients for treatment with oral MKIs
Track 15	Treatment after progression on sunitinib or sorafenib
Track 16	Predictors of response to targeted biologic agents
Track 17	ECOG-E2805: Phase III trial of adjuvant sunitinib versus sorafenib versus placebo in patients with resected renal cell carcinoma
Track 18	Impact of nephrectomy on metastatic disease

Case Discussions   Click here to download the Case Discussions
Track 1	Case discussion: A 59-year-old man presenting with metastatic renal cell carcinoma
Track 2	Biology of clear cell carcinomas
Track 3	Impact of Furman grade on long-term outcome
Track 4	Case discussion: A 63-year-old man with rapidly progressive clear cell carcinoma
Track 5	Phase III trial of sunitinib versus interferon-alpha as first-line therapy for metastatic renal cell cancer
Track 6	Tolerability of sunitinib and sorafenib
Track 7	Selection of systemic therapy for metastatic clear cell carcinoma
Track 8	Management of elderly patients with metastatic renal cell carcinoma
Track 9	Cardiac safety issues with sunitinib
Track 10	Potential role of mTOR inhibitors in the management of poor-risk renal cancer
Track 11	Tolerability of sorafenib versus sunitinib
Track 12	Selection of therapy after progression on an oral MKI
Track 13	Clinical use of bevacizumab in the management of metastatic renal cell carcinoma
Track 14	Two case presentations: Stage IV NED and adjuvant settings
Track 15	Potential role of oral MKIs in the adjuvant setting
Track 16	Predictors of response to oral MKIs
Track 17	Oral MKIs in other tumor types
Track 18	Tolerability and efficacy of oral MKIs in combination with bevacizumab
Track 19	Clinical use of oral MKIs in the adjuvant setting
Track 20	Trials of bevacizumab in the adjuvant setting
Track 21	Case discussion: A 74-year-old man with bilateral clear cell carcinoma
Track 22	Oral MKIs in patients with renal impairment
Track 23	Dosing sunitinib and sorafenib in patients with renal impairment
Track 24	Case discussion: A 63-year-old man with moderately differentiated papillary carcinoma and poor hepatic function
Track 25	Chemotherapy in the management of papillary carcinoma
Track 26	Oral MKIs in the management of patients treated for brain metastasis
Track 27	Duration of therapy with oral MKIs
Track 28	Time course for initiating surgery and restarting treatment with oral MKIs
Track 29	Importance of evaluating scans in determining progression
Track 30	Bevacizumab-related proteinuria

Ronald M Bukowski, MD Director, Experimental Therapeutics Cleveland Clinic Foundation Taussig Cancer Center Professor of Medicine CCF Lerner College of Medicine of Case Western Reserve University Cleveland, Ohio     Click here to download the entire interview
Track 1	Introduction
Track 2	Response to chemotherapy in patients with VHL gene mutation
Track 3	Responsiveness of non-VHL-mutated renal cell cancers to systemic therapies
Track 4	ASCO 2005 and 2006 and renal cell cancer
Track 5	Mechanisms of action of oral MKIs and monoclonal antibodies in renal cell cancer
Track 6	Similarities and differences between oral MKIs
Track 7	Selection of therapy after progression on an oral MKI
Track 8	Combining biologic agents in the management of renal cell cancer
Track 9	Side effects and toxicity of sunitinib versus sorafenib
Track 10	Sunitinib-associated hypothyroidism
Track 11	Skin toxicity and diarrhea associated with sorafenib
Track 12	Cardiotoxicity associated with sunitinib
Track 13	Clinical development of temsirolimus
Track 14	Current clinical algorithm for management of patients with metastatic renal cell cancer
Track 15	Clinical use of oral MKIs in the adjuvant setting

Janice P Dutcher, MD Professor of Medicine New York Medical College Associate Director for Clinical Affairs Comprehensive Cancer Center Our Lady of Mercy Medical Center Bronx, New York     Click here to download the entire interview
Track 1	Introduction
Track 2	Continuing an oral MKI after disease progression
Track 3	Comparative side effects and toxicity of sorafenib and sunitinib
Track 4	Selection of first-line therapy
Track 5	Clinical research strategies being evaluated in the adjuvant setting
Track 6	Efficacy and tolerability of temsirolimus
Track 7	MKIs in other solid tumor types
Track 8	Clinical trial results with sorafenib
Track 9	EGFR inhibitors in the management of renal cell carcinoma
Track 10	Common questions about the treatment of renal cell cancer
Track 11	Management of side effects associated with MKIs